文献速递儿童青少年精神

一氧化氮介导的TSC2 S-亚硝基化驱动Shank3与Cntnap2孤独症模型中的mTOR失调

Nitric Oxide-Mediated S-Nitrosylation of TSC2 Drives mTOR dysregulation across Shank3 and Cntnap2 Models of Autism Spectrum Disorder.
PubMed 文献 · Mol Psychiatry · 2026-02-25

该研究在Shank3Δ4-22与Cntnap2(-/-)小鼠及孤独症儿童临床样本中,发现一氧化氮经S-亚硝基化修饰TSC2促其泛素化降解,导致mTOR信号过度激活;抑制nNOS或阻止TSC2 S-亚硝基化可改善孤独症样行为。

要点

  • Shank3与Cntnap2孤独症小鼠模型中TSC2 S-亚硝基化增加,TSC2蛋白经泛素化降解减少。
  • TSC2减少导致兴奋性与抑制性神经元mTOR信号失调,抑制nNOS可阻止该过程。
  • 阻止TSC2 S-亚硝基化的C203S突变可预防Shank3Δ4-22小鼠孤独症样行为。

核心结论

  • NO介导的TSC2 S-亚硝基化导致TSC2蛋白减少和mTOR信号过度激活,驱动孤独症样表型。

研究设计与样本

  • 研究使用Shank3Δ4-22和Cntnap2(-/-)两种孤独症小鼠模型及孤独症儿童临床样本。
  • 采用SNOTRAP方法评估S-亚硝基化蛋白质组变化。
  • 通过药理学抑制nNOS和构建TSC2 C203S突变体进行机制验证。

主要发现

  • SNO-蛋白质组系统生物学分析显示mTOR通路富集。
  • Shank3Δ4-22和Cntnap2(-/-)小鼠中TSC2 S-亚硝基化增加,经泛素化导致TSC2蛋白丢失。
  • 兴奋性和抑制性神经元中mTOR信号失调。
  • 药理学抑制nNOS可阻止TSC2 S-亚硝基化、mTOR过度激活和蛋白质翻译改变。
  • 孤独症儿童临床样本(含SHANK3突变和特发性孤独症)显示TSC2水平降低和mTOR信号活性增加。

关键数值与推荐

  • 在Shank3Δ4-22小鼠前额叶皮层注射TSC2 C203S突变体可预防孤独症样行为。

临床怎么用

  • 提示nNOS抑制或靶向TSC2 S-亚硝基化可能成为孤独症(包括SHANK3突变携带者)的潜在治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder characterized by core behavioral symptoms. We previously showed that nitric oxide (NO) plays a key role in ASD. However, the precise molecular mechanism through which NO acts via its posttranslational modification, S-nitrosylation (SNO), in ASD remains largely unknown. Emerging evidence, including our previous studies, suggests that the mechanistic target of the rapamycin (mTOR) signaling pathway plays a critical role in ASD pathophysiology. Our SNO-proteome systems biology analysis showed the enrichment of the mTOR pathway. In this study, we deciphered a novel mechanism of the cross talk between NO and mTOR pathway using two well-established mouse models as well as clinical samples of children with ASD. To assess changes in the SNO-proteome, we used the SNOTRAP method, revealing increased S-nitrosylation of tuberous sclerosis complex 2 (TSC2) in Shank3Δ4-22 and Cntnap2(-/-) mutant mice. We proved that this modification led to the loss of TSC2 protein via ubiquitination, resulting in dysregulated mTOR signaling in both excitatory and inhibitory neurons. Pharmacological inhibition of neuronal nitric oxide synthase (nNOS) successfully prevented TSC2 S-nitrosylation, mTOR overactivation, and altered protein translation in ASD models, highlighting NO's role in modulating mTOR function. To further validate the role of TSC2 S-nitrosylation in ASD, we generated a cysteine-to-serine mutation (C203S) in TSC2 to prevent its S-nitrosylation. Intracranial injection of the mutant TSC2 (C203S) in Shank3Δ4-22 mice in the prefrontal cortex prevented ASD-like behaviors, confirming the pathogenic role of NO-mediated TSC2 modification. Critically, analysis of clinical samples from children with ASD, including those with SHANK3 mutations and idiopathic ASD, revealed reduced TSC2 levels and increased mTOR signaling activity, further validating our findings. Collectively, this study uncovers a novel molecular mechanism by which S-nitrosylation disrupts TSC2 function, leading to aberrant mTOR signaling and ASD-like phenotypes. By revealing a unique SNO-TSC2-mTOR axis, our work deciphers the novel nitric oxide-mediated mTOR activation and opens new avenues for targeted therapeutic strategies in ASD, including those carrying SHANK3 mutations.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Ojha SK, Kartawy M, Hamoudi W, et al. Nitric Oxide-Mediated S-Nitrosylation of TSC2 Drives mTOR dysregulation across Shank3 and Cntnap2 Models of Autism Spectrum Disorder. Mol Psychiatry. 2026. PMID: 41741707. doi:10.1038/s41380-026-03514-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。